An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With Schizophrenia
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
This PHASE4 trial investigates Schizophrenia and is currently completed. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
For direct contact, visit the study record on ClinicalTrials.gov .